We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Bladder Cancer

Journal Scan / Research · January 05, 2022

Enfortumab Vedotin for Treatment of Urothelial Cancer



Additional Info

Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study
Cancer 2021 Dec 09;[EPub Ahead of Print], VS Koshkin, N Henderson, M James, D Natesan, D Freeman, A Nizam, CT Su, AR Khaki, CK Osterman, MJ Glover, R Chiang, D Makrakis, R Talukder, E Lemke, TA Olsen, J Jain, A Jang, A Ali, T Jindal, J Chou, TW Friedlander, C Hoimes, A Basu, Y Zakharia, PC Barata, MA Bilen, H Emamekhoo, NB Davis, SA Shah, MI Milowsky, S Gupta, MT Campbell, P Grivas, GP Sonpavde, D Kilari, AS Alva

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading